<a id="bm-comp-5646aa4e-70d7-4fb8-8598-71d45cb2f180" name="bm-comp-5646aa4e-70d7-4fb8-8598-71d45cb2f180" class="BMCustomAnchor"></a><table><tr><td bm-component-id="5646aa4e-70d7-4fb8-8598-71d45cb2f180" style="vertical-align: top; width:100.000000%;"><ul><li>Approval for Selektope extended one year</li><li>Routine SCPB step to ensure timely re-registration</li><li>Still expect a decision recommendation in H2'25</li></ul></td></tr></table><a id="bm-comp-2818d84c-fd8c-45b2-8ac0-60c728ef1796" name="bm-comp-2818d84c-fd8c-45b2-8ac0-60c728ef1796" class="BMCustomAnchor"></a><table><tr><td bm-component-id="2818d84c-fd8c-45b2-8ac0-60c728ef1796" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Current approval extended by one year</h3><p>As the current market approval for Medetomidine expires in June, I-Tech has received a one-year extension of its current approval for Selektope (Medetomidine) in the EU. The extension is a standard routine by the SCPB to allow enough time to carry out all the required actions for the ongoing re-registration process.</p><h3 class="bm-h3">EU re-registration process continues as planned</h3><p>In March the EU commission representatives met with the Standing Committee on Biocidal Products (SCPB) for an initial discussion on the input received during the public consultation for Selektope. We still expect a decision recommendation in H2'25.</p></td></tr></table>